Regulation of interleukin-6 fetoplacental levels could be involved in the protective effect of low-molecular weight heparin treatment on murine spontaneous abortion

American Journal of Reproductive Immunology

Volumn 51, Issue 2, 2004, Pages 160-165

  Gutiérrez, Gabriela ^a   Sarto, A ^b   Berod, L ^a   Canellada, A ^a   Gentile, T ^a   Pasqualini, S ^b   Margni, R A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Halitus Veterinaria   (Argentina)

Author keywords

CBA J x DBA 2 high resorption rate; Enoxaparin; Interleukin (IL) 6

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETOPLACENTAL UNIT; FETUS; FETUS RESORPTION; FETUS WASTAGE; INOCULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SPONTANEOUS ABORTION; SUPERNATANT; TH2 CELL;

EID: 1242330823     PISSN: 10467408     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.8755-8920.2003.00131.x     Document Type: Article

References (29)

1. Clark D, Ding JW, Chaouat G, Coulam C, August C, Levy G: The emerging role of immunoregulation of fibrinogen-related procoagulant Fg12 in the success or spontaneous abortion of early pregnancy in mice and humans. Am J Reprod Immunol 1999; 42:37-43.
2. Lin H, Mossman T, Guilbert L, Tuntipopipat S, Wegmann T: Synthesis of T helper 2 cytokines at the maternal fetal interface. J Immunol 1993; 151:4562-4573.
3. Gutiérrez G, Malan Borel I, Margni RA: The placental regulatory factor involved in the asymmetric IgG antibody synthesis responds to IL-6 features. J Reprod Immunol 2001; 49:21-32.
4. Hill JA, Polgar K, Anderson DJ: T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 1995; 273:1933-1936.
5. Tilg H, Dinarello CA, Mier JW: IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18:428-432.
6. Raghupathy R: Thl-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18:478-482.
7. Saito S: Cytokine network at the feto-maternal interface. J Reprod Immunol 2000; 47:87-103.
8. Chaouat G, Meliani A, Martal J, Raghupathy R, Elliot J, Mosmann T, Wegmann T: IL-10 prevents naturally occurring fetal loss in the CBA/J × DBA/2 mating combination and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFNγ. J Immunol 1995; 154:4261-4268.
9. Clark D, Chaouat G, Arck P, Mittruecker H, Levy G: Cytokine-dependent abortion in CBA/J × DBA/2 mice is mediated by the procoagulant fg12 prothrombinase. J Immunol 1998; 160:545-549.
10. Clark DA, Yu G, Levy GA, Gorczynski RM: Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. Semin Immunol 2001; 13:255-263.
11. Brenner B, Blumenfeld Z: Thrombophilia and fetal loss. Blood Rev 1997; 11:72-79.
12. Pihusch R, Buchholz T, Lohse P, Rübsamen H, Rogenhofer N, Hasbargen U, Hiller E, Thaler C: Trombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46:124-131.
13. Roubey RA: Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 2002; 14:238-242.
14. Brenner B, Hoffman R, Blumenfeld Z, Younis JS: Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83:693-697.
15. Sarto A, Rocha M, Geller M, Capmany C, Martinez M, Quintains C, Donaldson M, Pasqualini S: Treatment with enoxaparin adapted to the fertility program in women with early recurrent pregnancy loss and trombophilia. Medicina 2001; 61:406-412.
16. Schwab G, Siegall C, Aarden L, Neckers L, Nordan R: Characterization of an interleukin-mediated autocrine growth loop in the human multiple mieloma cell line U-266. Blood 1991; 77:587-593.
17. Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R: Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Int J Canc 1996; 65:498-505.
18. Blois SM, Zenclussen AC, Olmos S, Arias K, Roux ME, Margni R: Mice abortion could be mediated by enhanced interleukin-6 (IL-6) levels in placenta and decidua. Am J Reprod Immunol 2002; 47:369 (abstract).
19. Agarwal R, Loganath A, Roy AC, Wong YC, Lindoff C Ng SC: Increased expression of interleukin 6 in term compared to the first trimester human placental villi. Horm Metab Res 2000; 32:164-168.
20. Jauniaux E, Gulbis B, Shandene L, Collette J, Hustin J: Distribution of interleukin-6 in maternal and embryonic tissues during the first trimester. Mol Hum Reprod 1996; 2:239-243.
21. Jacobs AL, Sehgal PB, Julian J, Carson DD: Secretion and hormonal regulation of interleukin-6 production by mouse uterine stromal and polarized epithelial cells cultured in vitro. Endocrinology 1992; 131:1037-1046.
22. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M: A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 2002; 65:32-37.
23. Laurent P, Dussarat GV, Bonal J, Jego C, Talard P, Bouchiat C, Cellarier G: Low molecular weight heparins: a guide to their optimum use in pregnancy. Drugs 2002; 62:463-477.
24. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML: Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20:198-208.
25. Wei LH, Kuo ML, Chen CA, Cheng WF, Hsieh FJ, Hsieh CY: Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001; 82:49-56.
26. Chamorro A, Cervera A, Castillo J, Davalos A, Aponte JJ, Planas AM: Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients. Neurosci Lett 2002; 16:229-232.
27. Koller M, Kutscha-Lissberg F, Brom J, Weidinger G, Muhr G: Influence of low molecular weight heparin (certoparin) and unfractionated heparin on the release of cytokines from human leukocytes. Inflammation 2000; 25:331-337.
28. Mummery R, Rider C: Characterization of the heparin-binding properties of IL-6. J Immunol 2000; 15:5671-5679.
29. Clark D, Chaouat G, Gorczynski R: Thinking outside the box: mechanisms of environmental selective pressures on the outcome of the materno-fetal relationship. Am J Reprod Immunol 2002; 47:275-282.